Xavier Maldonado

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Journal: Clinical and translational radiation oncology

Published: April 17, 2026

Position paper of the Spanish Society of Radiotherapeutic Oncology (SEOR) and its genitourinary tumors group (URONCOR) on the prescription of parp inhibitors in advanced prostate cancer.

Position paper of the Spanish Society of Radiotherapeutic Oncology (SEOR) and its genitourinary tumors group (URONCOR) on the prescription of parp inhibitors in advanced prostate cancer.

Journal: Actas urologicas espanolas

Published: February 23, 2026

Poorly differentiated neuroendocrine transformation from metastatic upper tract urothelial carcinoma.

Poorly differentiated neuroendocrine transformation from metastatic upper tract urothelial carcinoma.

Journal: BMJ case reports

Published: February 12, 2026

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2025

Combined neuroendocrine carcinoma of the penis: clinical, pathological and therapeutic insights.

Combined neuroendocrine carcinoma of the penis: clinical, pathological and therapeutic insights.

Journal: BMJ case reports

Published: July 01, 2025

Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial.

Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial.

Journal: Actas urologicas espanolas

Published: March 11, 2025

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 10, 2025

Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.

Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 15, 2024

A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.

A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.

Journal: BJU international

Published: July 23, 2024

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.

Journal: Cell reports. Medicine

Published: July 21, 2024

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Journal: Lancet (London, England)

Published: June 03, 2024

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.

Journal: European urology

Published: May 20, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026